| タイトル（別表記） | An investigator initiated phase II clinical trial of tamibarotene (AM80G) for chronic graft-versus-host disease |
|---|---|
| フルテキストURL | 127_133.pdf |
| 著者 | 西森 久和| 前田 嘉信| |
| キーワード | 臨床研究中核病院 慢性GVHD タミバロテン 同種造血幹細胞移植 Th17 |
| 出版物タイトル | 岡山医学会雑誌 |
| 発行日 | 2015-08-03 |
| 巻 | 127巻 |
| 号 | 2号 |
| 開始ページ | 133 |
| 終了ページ | 137 |
| ISSN | 0030-1558 |
| 関連URL | isVersionOf https://doi.org/10.4044/joma.127.133 |
| 言語 | 日本語 |
| 著作権者 | Copyright (c) 2015 岡山医学会 |
| 論文のバージョン | publisher |
| DOI | 10.4044/joma.127.133 |
| NAID | 130005096255 |
| JaLCDOI | 10.18926/AMO/49251 |
|---|---|
| フルテキストURL | 67_1_1.pdf |
| 著者 | Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune| |
| 抄録 | Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th17 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment. |
| キーワード | chronic GVHD Th17 Am80 regulatory T cell (Treg) steroid-refractory |
| Amo Type | Review |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2013-02 |
| 巻 | 67巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 1 |
| 終了ページ | 8 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2013 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 23439503 |
| Web of Science KeyUT | 000316829900001 |
| フルテキストURL | fulltext20240213-01.pdf |
|---|---|
| 著者 | Urata, Tomohiro| Naoi, Yusuke| Jiang, Aixiang| Boyle, Merrill| Sunami, Kazutaka| Imai, Toshi| Nawa, Yuichiro| Hiramatsu, Yasushi| Yamamoto, Kazuhiko| Fujii, Soichiro| Yoshida, Isao| Yano, Tomofumi| Chijimatsu, Ryota| Murakami, Hiroyuki| Ikeuchi, Kazuhiro| Kobayashi, Hiroki| Tani, Katsuma| Ujiie, Hideki| Inoue, Hirofumi| Tomida, Shuta| Yamamoto, Akira| Kondo, Takumi| Fujiwara, Hideaki| Asada, Noboru| Nishimori, Hisakazu| Fujii, Keiko| Fujii, Nobuharu| Matsuoka, Ken-ichi| Sawada, Keisuke| Momose, Shuji| Tamaru, Jun-ichi| Nishikori, Asami| Sato, Yasuharu| Yoshino, Tadashi| Maeda, Yoshinobu| Scott, David W.| Ennishi, Daisuke| |
| 発行日 | 2023-12-14 |
| 出版物タイトル | Blood Advances |
| 巻 | 7巻 |
| 号 | 24号 |
| 出版者 | American Society of Hematology |
| 開始ページ | 7459 |
| 終了ページ | 7470 |
| ISSN | 2473-9529 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2023 by The American Society of Hematology. |
| 論文のバージョン | publisher |
| PubMed ID | 37552496 |
| DOI | 10.1182/bloodadvances.2023010402 |
| Web of Science KeyUT | 001141306600001 |
| 関連URL | isVersionOf https://doi.org/10.1182/bloodadvances.2023010402 |
| JaLCDOI | 10.18926/AMO/66915 |
|---|---|
| フルテキストURL | 78_2_123.pdf |
| 著者 | Saeki, Kyosuke| Fujiwara, Hideaki| Seike, Keisuke| Kuroi, Taiga| Nishimori, Hisakazu| Tanaka, Takehiro| Matsuoka, Ken-ichi| Fujii, Nobuharu| Maeda, Yoshinobu| |
| 抄録 | Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HCT), but its pathogenesis remains unclear. Recently, haplo-identical HCT with post-transplant cyclophosphamide (Haplo-HCT with PTCY) was found to achieve a low incidence rate of acute GVHD and chronic GVHD. However, while the pathogenesis of acute GVHD following Haplo-HCT with PTCY has been well investigated, that of chronic GVHD remains to be elucidated, especially in HLA-matched HCT with PTCY. Based on its safety profile, PTCY is currently applied for the human leucocyte antigen (HLA)-matched HCT setting. Here, we investigated the mechanisms of chronic GVHD following HLA-matched HCT with PTCY using a well-defined mouse chronic GVHD model. PTCY attenuated clinical and pathological chronic GVHD by suppressing effector T-cells and preserving regulatory T-cells compared with a control group. Additionally, we demonstrated that cyclosporine A (CsA) did not show any additional positive effects on attenuation of GVHD in PTCY-treated recipients. These results suggest that monotherapy with PTCY without CsA could be a promising strategy for the prevention of chronic GVHD following HLA-matched HCT. |
| キーワード | GVHD posttransplant cyclophosphamide hematopoietic cell transplantation HLA-identical |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2024-04 |
| 巻 | 78巻 |
| 号 | 2号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 123 |
| 終了ページ | 134 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2024 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |